Brought to you by 
BMS partners Recothrom with The Medicines Co. for two years with option to buy; exercised
30 Jan 2023
Executive Summary
Bristol-Myers Squibb Co. has granted The Medicines Co. (TMC; hospital products) a two-year license to its active hemostat Recothrom (recombinant human thrombin) worldwide, excluding Canada.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS partners Recothrom with The Medicines Co. for two years with option to buy; exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice